China Cycle 2024 Provides International Bicycle Exhibition Analysis

The 32nd China International Bicycle Fair (CHINA CYCLE 2024 in abbreviation), with the theme “New Track, New Power, New Journey,” has been grandly held from May 5th to 8th, 2024 at Shanghai New International Expo Center. Recently, China Cycle 2024 provided its International Bicycle Exhibition Analysis.

I. The popularity of CHINA CYCLE continues to rise

Despite the huge pressure from domestic and foreign markets this year, CHINA CYCLE this year was still very popular.

1. Exhibition Scale

The total exhibition area of CHINA CYCLE 2024 is 150,000 ㎡. There are 12 indoor exhibition halls and 1 outdoor exhibition hall together with outdoor test ride and activity areas.

2. Participating Countries and Regions

1,460 exhibitors participated in CHINA CYCLE 2024 with 7,360 booths, including many leading enterprises in the two wheel industry. Among them are 109 overseas exhibitors with 621 booths from 23 countries and regions, including Germany, Belgium, France, United Kingdom, Italy, the Netherlands, Denmark, Spain, Portugal, Slovakia, Slovenia, Russia, the United States, New Zealand, Japan, South Korea, India, Pakistan, Sri Lanka, Israel, Singapore, Taiwan Province and Hong Kong S.A.R. etc.

3. Visitor Data

The total number of visitor is 141,266 (including 126,262 domestic visitors and 15,004 overseas visitors), the total number of entrance is 192,941 person times. Overseas visitors are from 133 countries and regions. Top ten are India, Russia, South Korea, Japan, the United States, Thailand, Malaysia, Brazil, Indonesia and Australia.

II. A variety of Fashion Events

CHINA CYCLE 2024 has many concurrent activities, such as the meeting between both sides of the Taiwan Straits, the working conference of the bicycle parts professional technical committee of China bicycle association, the international sourcing meeting, the online trade matching meeting, the creative demonstration exhibition, the demonstration exhibition of industry transformation and upgrading etc.In addition, the organizing committee has also elaborately provided a variety of interactive activities for the visitors, such as E-sports championship, electric assisted bicycle test riding, children’s bike riding, bicycle market, etc. They have attracted many exhibitors and visitors. Otherwise, many exhibitors have also held a variety of activities in their respective exhibition areas, such as e-bike competitions, cycling culture quizzes, brand knowledge quizzes, etc. These activities combining bicycle culture with fitness and environmental protection have become a beautiful landscape and brought many highlights and charm to CHINA CYCLE.

The bicycle market was set up for the first time this year. It is not only a display of products, but also a story about lifestyle. Every visitor could further understand the connotation and charm of bicycles by on-site activities like situational experience and interactive communication. The representatives from dozens of clubs and enthusiast groups gathered at the market to jointly create a space for making friends and showing talents by bicycles. With them the visitors could embark on a journey to explore the new world of fashionable cycling.

In recent years, a large area for E-bikes test riding has been set aside in the fair. E-bike has become the first choice for cyclists abroad, especially in Europe and the United States, because it can be for both commuting and fitness, particularly for riding on a distance of about 10 km or on a sloped road. In China, E-bike is still in the popularization stage. In order to let more enthusiasts know about this fashionable vehicle, the organizing committee spared no effort to promote it and continued to set up experience space for test riding.

III. Adding exhibition halls to meet the needs of enterprises

The organizing committee decided to expand the exhibition area, namely added two new exhibition halls based on the summary and analysis to meet the display needs of enterprises. In the face of the enterprises’ enthusiasm to participate in the fair, the organizing committee communicated actively and tried the best to solve the booths problem for exhibitors. The new exhibition hall W5 introduced the theme of E-motorcycles, which attracted the attention of a large number of visitors. It took another step forward to meet the market demand and complete the two-wheel product display section. Before the fair, the organizing committee coordinated with many parties and added exhibition hall S outside the venue to meet the needs of exhibitors as much as possible. Finally, 12 thematic exhibition halls (Halls E1-E7, Halls W1-W5) and 1 outdoor exhibition hall (Hall S) were opened.

IV. Active communication to provide conditions for enterprises to go overseas

At CHINA CYCLE, export has always been one of the main purposes of enterprises’ participation. In the last few years, due to the impact of the epidemic, the number of overseas visitors was limited. In order to change this unfavorable situation as soon as possible, the organizing committee took multiple measures to match cross-border trade as much as possible: first, it held the international sourcing meeting for three straight years, combining online and on-site and with multiple interactive scenarios to meet the trade negotiations with different forms of procurement needs. Second, it cooperated with main global media platforms to spread the exhibition information to the world. Third, it promoted by personal media platforms to make an impact and attract global professional buyers to visit the fair. Fourth, it invited global industry organizations to participate in the fair as a group, and invited nearly 100 overseas buyers (mainly the overseas buyers resident in China from the Middle East, Africa, South America, Japan, South Korea, Southeast Asia, etc.) to the site.

V. Focus on innovation, highlight scientific and technological achievements

CHINA CYCLE is a weathervane for the development of the bicycle industry and a window for enterprises to test and display the new products. Many industry-leading technology products can be seen at the fair, such as: intelligent, new functions, products with new materials, etc. These products have or are about to enter the consumer market to play a leading role in market development and upgrading.

As the star event of the fair, 2024 CHINA CYCLE “Creative Demonstration Exhibition” became the focus with 15 gold and 55 excellent award products which stood out from more than 200 participating products. Since its inception, the “Creative Demonstration Exhibition” has been the focus of the industry for 14 consecutive years with its unique charm. Each CHINA CYCLE attracts more than 100 innovative products to sign up and compete to show their talents on this stage. This year, a review area of ​​award-winning products over the years was specially set up, so that the visitors can take a look at the top products in the industry over the past decade. Many visitors stopped in front of the exhibition to watch and take photos in order to provide reference for the future development. The “Creative Demonstration Exhibition” not only shows the peak of product innovation in the bicycle and E-bikes industry, but also proves the amazing transformation strength of the scientific and technological achievements.

Attaching importance to the scientific and technological content of the fair, leading with science and technology, helping the industry continuously innovate and progress have become the important tasks in organizing a successful CHINA CYCLE.

VI. Data Analysis

Media Contact
Company Name: Shanghai OTOBTB Cultural Development Co.,Ltd
Contact Person: Kira Pan
Email: Send Email
Country: China
Website: http://www.otobtb.com

No More Trash Stress: Jordan Disposal Introduces Premium Dumpster Service in NWA

No More Trash Stress: Jordan Disposal Introduces Premium Dumpster Service in NWA
Say goodbye to the hassle and inconvenience of managing waste, as Jordan Disposal brings a new level of premium waste management services to NWA.

Say goodbye to the hassle and inconvenience of managing waste, as Jordan Disposal brings a new level of premium waste management services to NWA. Residents and businesses can now experience the convenience and luxury of Jordan Disposal’s top-tier dumpster rentals, eliminating the stress and eyesores associated with overflowing bins and neglected trash piles.

“Northwest Arkansas is growing rapidly, and so is its need for reliable, premium waste management solutions,” said Michelle Murphy of Jordan Disposal. “We’re stepping up to meet that demand with our state-of-the-art dumpsters and convenient rental service, which we believe will contribute to a cleaner, more prosperous Northwest Arkansas.”

With Jordan Disposal’s premium dumpster rental in Northwest Arkansas, even the most daunting cleanup projects become manageable. The company’s commitment to providing a variety of dumpster sizes ensures that every customer finds the ideal container for their specific needs, whether it’s disposing of yard waste or managing construction debris. This flexibility, combined with the company’s dedication to timely delivery and pickup, makes Jordan Disposal a reliable partner for any project requiring efficient waste removal.

Beyond dumpster rentals, consistent and reliable dumpster service in NWA is essential for maintaining clean and healthy living environments. Regular waste removal is crucial for preventing the buildup of garbage, which can attract pests such as rodents and insects, create unpleasant odors that affect the quality of life, and pose potential health risks through the spread of bacteria and disease. Jordan Disposal’s waste management service ensures that household waste is collected promptly and efficiently, minimizing these nuisances and contributing to a more pleasant and inviting community atmosphere where residents are free to enjoy their outdoor spaces, entertain guests, and take pride in the appearance of their neighborhoods.

With a rich history of its own, Jordan Disposal NWA has been providing exceptional waste management services without compromising on quality or environmental responsibility. The company’s expansion into Northwest Arkansas represents a natural progression of its mission to provide reliable, efficient, and eco-friendly waste solutions to communities throughout the region. Known for its commitment to customer satisfaction, innovative practices, and sustainable solutions, Jordan Disposal is well-equipped to handle the diverse waste management needs of the growing Northwest Arkansas region.

For more information about Jordan Disposal’s premium dumpster rental service in Northwest Arkansas, please visit the company’s website at https://jordandisposal.com/location/arkansas/

Media Contact
Company Name: Jordan Disposal
Contact Person: Mads Gisselbaek
Email: Send Email
Phone: (888) 624-4469
Address:15645 AR-72
City: Gravette
State: AR
Country: United States
Website: https://jordandisposal.com/

GCS Glass Raises a Toast to Austin Wine Lovers: New Wine Cellar Buying Guide Unveiled

GCS Glass Raises a Toast to Austin Wine Lovers: New Wine Cellar Buying Guide Unveiled
In a move that’s sure to delight Austin’s wine lovers, GCS Glass, the purveyor of exceptional glass craftsmanship, unveils its comprehensive buying guide for wine cellars. Designed to elevate the wine storage experience, this meticulously curated resource provides wine enthusiasts with the knowledge and tools necessary to curate their perfect wine havens.

In a move that’s sure to delight Austin’s wine lovers, GCS Glass, the purveyor of exceptional glass craftsmanship, unveils its comprehensive buying guide for wine cellars. Designed to elevate the wine storage experience, this meticulously curated resource provides wine enthusiasts with the knowledge and tools necessary to curate their perfect wine havens. Whether a seasoned collector or a budding connoisseur, this guide offers expert insights, practical tips, and a curated selection of essentials to ensure a seamless and inspiring journey of building or upgrading a wine cellar.

“Austin’s love for wine is undeniable, and we’re thrilled to offer a resource that caters to this passion,” enthused Robert Gomez of GCS Glass. “Our wine cellar buying guide is a testament to our commitment to helping wine enthusiasts create personalized wine storage solutions that reflect their unique tastes and elevate their enjoyment of every sip.”

Austin’s burgeoning culinary scene and growing appreciation for fine wines have fueled an unprecedented demand for custom wine cellars. Proper storage is paramount to preserving each bottle’s quality, character, and value, making a well-designed wine cellar essential for any serious collector. With this in mind, GCS Glass’ buying guide for wine cellars in Austin, TX, offers valuable insights into the factors contributing to optimal wine storage, including temperature, humidity, lighting, and vibration control.

However, modern wine enthusiasts are not just seeking functional storage solutions; they want their cellars to reflect their style and passion for wine. Gone are the days of dark, hidden cellars. Today’s collectors crave stylish, eye-catching displays that elevate wine storage to an art form. GCS Glass’s guide showcases this evolution, highlighting the rising popularity of glass wine cellars that protect precious vintages and serve as stunning focal points in any home. With options ranging from space-saving wine walls to statement-making freestanding cellars, the guide outlines the various types available, each designed to meet modern collectors’ unique needs and preferences. For inspiration and guidance in selecting the perfect wine storage solution for homes and businesses, click here for more information.

GCS Glass Austin, TX, has established a reputation for exceptional craftsmanship and innovative design. With a passion for creating bespoke glass solutions, the company has become a trusted partner for homeowners and businesses seeking to elevate their spaces with elegant and functional glass installations. Their commitment to quality, combined with a deep understanding of local aesthetics and preferences, has made them a sought-after provider for those looking to enhance their homes and businesses with the timeless beauty of glass.

For a comprehensive look at GCS Glass’s innovative wine cellar solutions, please visit their website at https://gcsglassandmirror.com/locations/austin-tx/. Wine enthusiasts are encouraged to explore the full wine cellar buying guide for expert insights and inspiration.

Media Contact
Company Name: GCS Glass & Mirror – Austin
Contact Person: Chance Forman
Email: Send Email
Phone: 512-400-2949
Address:10509 Circle Dr.
City: Austin
State: TX
Country: United States
Website: https://gcsglassandmirror.com/locations/austin-tx/

WorldLeagueLive! Creating a New Era of Gaming Entertainment and Fan Economy

WorldLeagueLive! (WLL) is revolutionizing the sports and gaming landscape by seamlessly integrating gaming entertainment with the fan economy through its innovative gaming ecosystem.

WorldLeagueLive! is a dynamic player-versus-player (PVP) football game that allows you to play with friends and even challenge football stars in real-time through the “Play with Stars” feature. With simplified rules, an intuitive PVP mechanism, and online football competitions, WLL draws more people into the joy of football while pioneering a new online ecosystem.

A Relaxed and Enjoyable Gaming Experience

WLL offers a relaxed and enjoyable gaming experience with its simplified four-a-side football rules. Unlike traditional football games that are pay-to-play or require many hours to master, WLL focuses on social interaction and entertainment, making it easy for players to jump in and have fun.

Integrating NFT and Live Streaming Technologies

WLL integrates NFT and live-streaming technologies, allowing players to collect valuable NFTs to use as in-game items. Through official collaborations with football stars, celebrities, and clubs, players can directly interact with them in the game and stream content for free, in real-time!

Bridging the Gap Between Users and Football Stars

Through its game content and social features, WLL truly connects football stars with their fans. Partnerships with stars like Arat, Alessandro Del Piero, and top clubs from the world’s five major leagues enrich the game content and offer fans opportunities to interact with their idols, making the gaming experience even more thrilling and engaging.

Solving the Challenges of Traditional and Web3 Games

The design philosophy of WLL addresses the limitations of traditional sports games. Previous video games, despite providing casual entertainment, have failed to effectively integrate the fan economy and thus lack long-term development potential. Many past Web3 game projects have struggled to balance fun and profit, leading to short lifespans.

WLL solves these issues by seamlessly integrating the fan economy, gaming entertainment, and Web3 technology to develop a stable and sustainable ecosystem, creating an innovative economic model that also drives social interactions.

Looking Ahead

The future of WLL is brimming with endless possibilities. As technology advances and gamer demands evolve, the platform will continue to innovate, offering increasingly diverse and personalized gaming experiences. WLL is leading the way in gaming entertainment with its cutting-edge technology and distinctive concept where players are essential participants in the ecosystem. Every interaction and contribution players make helps advance the entire platform.

Football is merely the initial phase for WLL. Moving forward, the platform will encompass basketball, ice hockey, tennis, and more! WLL’s ultimate objective is to create the largest global platform for fan interaction across all sports, utilizing gaming as the medium and interaction as the cornerstone to connect fans with sports stars. Francesco, the project founder and industry veteran with over a decade of experience, is focused on building an innovative fusion of football, esports, and Web3. Join us on this exciting journey!

Media Contact
Company Name: World league live
Contact Person: Marketing Team
Email: Send Email
Address:103 TAMPINES STREET 86, #03-06, THE ALPS RESIDENCES
Country: Italy
Website: https://worldleaguelive.com/

The Power Cord Reels Market Revenue to Hit $2.25 Billion by 2029 – the Offline Sales Channel to Remain Dominant – Arizton

“Power Cord Reels Market Report by Arizton”
Introducing Our Exclusive Subscription Model! Discover All the Benefits Today

According to the latest research report titled, the power cord reels market 2024-2029 by Arizton Advisory & Intelligence, the market will grow at a CAGR of 2.25% during 2023-2029.  

 

Curious to Learn more about the report? Click: https://www.arizton.com/market-reports/cord-reels-market

 

Report Summary:

Market Size (2029): USD 2.25 Billion

Market Size (2029): USD 1.65 Billion

CAGR (2023-2029): 5.37%

Historic Year: 2020-2022

Base Year: 2023

Forecast Year: 2024-2029

Market Segmentation: Reel Type, Reel Length, End-User, Commercial, Industrial, Public & Recreational, Distribution Channel, and Geography

Geographical Analysis: North America, Europe, APAC, Latin America, and Middle East & Africa

 

Subscribe us for more updates: https://www.arizton.com/subscription

 

The presence of leading brands in the power cord reels industry has resulted in substantial global exports, with major exporters such as the US, South Korea, Germany, and Japan dominating the market. Industrialized countries in Europe and North America, such as Germany, France, the UK, the US, and Canada, are driving the demand for various electric tool products. These nations aim to boost the productivity of their manufacturing operations by using high-performance, value-added equipment. As these tools often require power sockets that may not be readily available, power cord reels are essential, thereby supporting the growth of the power cord reels market.

 

Market Opportunities & Trends

Logistics companies strengthen the economy of the US by bringing in trillions of dollars a year . For instance, in 2018, the global market was worth an estimated $9.6 trillion and is expected to rise to $15 trillion by 2023. In addition, the rapid growth in e-commerce businesses, such as Amazon and Alibaba, drives the logistics market as they enable businesses to ship orders to customers. The US retail e-commerce sales for the third quarter of 2021 were $214.6 billion. The e-commerce business has accelerated and contributed to the rising demand for online shopping across the globe . This industry growth has indirectly contributed to increased demand for logistics services, which is expected to drive the need for warehouses and storage units to ensure smooth transport and storage of their goods. Hence, the development of these facilities will indirectly impact the power cord reels market.

Several automotive manufacturers invested in research and development (R&D) initiatives due to the emergence of new technologies and regulations. For instance, the R&D spending on automotive vehicles by Tata Motors in 2024 is estimated to reach $124.08 million, according to the company’s annual fillings. Such initiatives will enable these companies to launch passenger cars that are appealing to the market. Exponential investments in R&D initiatives enabled companies such as Hyundai, Kia, Tata Motors, and SAIC Motors to deliver high-quality passenger vehicles at reasonable prices to cater to the price-sensitive consumer segment. Thus, all these factors played an instrumental role in the growing demand for passenger vehicles in emerging economies, thereby driving the power cord reels market growth.

 

Offline Distribution Channel to Play a Major Role in the Market

The global offline power cord reels market to be worth $1.4 billion by 2029.

The offline distribution channel is one of the oldest and most established methods for selling, introducing, and marketing products to potential customers. In 2022, it accounted for 91% of total distribution methods for power cord reels and is expected to grow throughout the forecast period. This preference is primarily due to customers’ desire to fully understand the functions and features of power cord reels, which is a critical aspect of the market.

Unlike the online distribution channel, the offline method allows customers to receive product demonstrations and use the products before making a purchase. Customers can also check the quality, colors, sizes, and other aspects in person, which significantly influences their purchasing decisions. These factors are anticipated to drive the sales of power cord reels through the offline channel during the forecast period.

Globally, one of the primary methods of equipment sales is through dealers and distributors, who play a crucial role in reaching potential customers. These intermediaries sell power cord reels from original equipment manufacturers and provide essential technical support and customer service. Efficient and timely dealers contribute significantly to brand loyalty and customer consideration, highlighting the importance of the offline distribution channel in the power cord reels market.

 

Post-Purchase Benefit                    

  • 1hr of free analyst discussion                    
  • 10% off on customization 

 

Key Company Profiles

  • Madison Industries
  • Cox Reels
  • Stanley Black & Decker
  • Henny Reels INC
  • Unique Hosereels
  • Molex
  • Ametek Inc
  • Hubbell Incorporated
  • Schill Gmbh & Co
  • Cavotec SA
  • Bayco Products Inc
  • Lind Equipment
  • Legacy Manufacturing
  • Luceco Plc
  • Iron Forge Tools
  • Alert Reel Manufacturing
  • Schnieder Electric
  • KH Industries

 

Market Segmentation

 

Reel Type

  • Spring Loaded & Retractable
  • Motor
  • Manual

 

Reel Length

  • Below 75 Feet
  • Above 75 Feet

 

End-User

  • Commercial
  • Public & Recreational
  • Industrial
  • Residential
  • Others

 

Commercial

  • Construction Sites
  • Workshops & Garages
  • Hospitals & Labs
  • Others

 

Industrial

  • Manufacturing
  • Logistics & Warehousing
  • Automotive
  • Others

 

Public & Recreational

  • School & Universities
  • Event Organizers
  • Sports Facilities
  • Others

 

Distribution Channel

  • Offline
  • Online

 

Geography

  • North America
    • The US
    • Canada
  • Europe
    • Germany
    • The UK
    • France
    • Italy
    • Russia
    • Spain
    • Netherlands
    • Sweden
  • APAC
    • China
    • Japan
    • India
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • South Africa
    • The UAE

 

Check Out Some of the Latest Research Report that Can Boost your Business Decisions  

Outdoor Litter Vacuum Market – Global Outlook & Forecast 2024-2029

https://www.arizton.com/market-reports/outdoor-litter-vacuum-market

Central Vacuum System Market – Global Outlook & Forecast 2024-2029

https://www.arizton.com/market-reports/central-vacuum-system-market

 

Why Arizton?                          

100% Customer Satisfaction                          

24×7 availability – we are always there when you need us                          

200+ Fortune 500 Companies trust Arizton’s report                          

80% of our reports are exclusive and first in the industry                          

100% more data and analysis                          

1500+ reports published till date                           

 

About Us:                                                               

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                             

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                              

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.            

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1 3122332770
Country: United States
Website: https://www.arizton.com/market-reports/cord-reels-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Power Cord Reels Market Revenue to Hit $2.25 Billion by 2029 – the Offline Sales Channel to Remain Dominant – Arizton

Cold Storage Market to Hit USD 12.22 Billion by 2029 – Market Size, Share, Trend Analysis & Forecasts – Exclusive Research Report by Arizton

“Cold Storage Market Research Report by Arizton”
The chilled storage segment, which typically refers to storage at temperatures between 0°C and 5°C, held the largest share of the global cold storage market in 2023.

According to the latest research report, the Cold Storage Market 2024-2029 by Arizton Advisory & Intelligence will grow at a CAGR of 7.70% during 2023-2029.

The global cold storage market plays a crucial role in maintaining the quality and safety of various products, including food and pharmaceuticals, by preserving them at specific temperatures. In addition, the cold storage market has been expanding steadily over the past few years and is expected to continue growing. Factors such as increasing demand for frozen and chilled food products, expanding pharmaceutical and healthcare industries, and the need for efficient supply chain management contribute to this growth.

 

Curious to Learn More,Click: https://www.arizton.com/market-reports/cold-storage-market

 

Report Summary

Market Size Revenue (2029): USD 12.22 Billion

Market Size Revenue (2023): USD 7.83 Billion

CAGR – Revenue (2023-2029): 7.70%

Market Size – Volume (2029): 1,064.52 million cubic meters

Historic Year: 2020-2022

Base Year: 2023

Forecast Year: 2024-2029

Market Segmentation: Warehouse Type, Facility Type, Temperature Type, Structure Type, Application, and Geography

Geographic Analysis: North America, Europe, APAC, Latin America, and Middle East & Africa

 

Subscribe us for more updates: https://www.arizton.com/subscription

 

Refrigerated Warehouses Leading the Market

The global refrigerated warehouse market will reach $3.2 billion by 2029, growing at a CAGR of 6.94% during the forecast period.

Refrigerated warehouses maintain consistent temperature and humidity levels, preserving the quality, freshness, and nutritional value of perishable goods such as fruits, vegetables, meats, seafood, dairy products, and pharmaceuticals. By preventing spoilage, freezer burn, and microbial growth, these facilities extend the shelf life of products, reducing waste. Furthermore, in North America and Europe, the surge in e-commerce and online grocery shopping has led to greater demand for refrigerated warehouses capable of storing and distributing perishable goods for home delivery and click-and-collect services. As consumers embrace online grocery shopping, retailers and logistics providers invest in cold storage infrastructure to meet the demand for fresh and frozen products.

 

More than $4.8 Billion Growth Opportunities in the APAC Cold Storage Market

The cold storage market in APAC has been experiencing significant growth in recent years. According to GCCA, the region represents more than 300 cold chain suppliers and logistics providers in more than 15 countries. Hence, massive cold chain suppliers in the region significantly support the cold storage market.

China has released a National Logistics Hub Layout and Construction Plan to improve infrastructure and logistics capabilities, aiming to establish 150 advanced logistics hubs by 2025. In addition, during the 14th Five-Year Plan period (2021-2025), the country expects to set up 30 national and 70 regional cold-chain logistics bases for agricultural products. Similarly, the Indian government has also invested heavily in the industry and encouraged private participation through various subsidy schemes, such as the Pradhan Mantri Kisan Sampada Yojana and the Mission for Integrated Development of Horticulture scheme, both provide financial support in the form of grants-in-aid, such initiatives are positively impacting the cold storage market in the region. 

 

To Know More, Click: https://www.arizton.com/market-reports/cold-storage-market

 

Key Company Profiles

  • Lineage Logistics Holding, LLC
  • Americold Logistics
  • United States Cold Storage, Inc
  • NewCold
  • Nichirei Corporation
  • Emergent Cold LatAM
  • The Tippmann Group
  • Constellation Cold Logistics
  • Superfrio Logistica Frigorificada
  • FreezPak Logistics
  • Conestoga Cold Storage
  • Congebec Logistics, Inc.
  • Metcold Holdings Limited
  • RLS Logistics
  • Friozem Armazens Frigorificos
  • Magnavale Ltd
  • Trenton Cold Storage
  • Nor-Am Cold Storage
  • Burris Logistics
  • Arihant Cold Storage
  • ColdStar Solutions Pvt Ltd
  • ColdStar Logistics
  • Coldman Logistics Pvt Ltd
  • Coldrush Logistics
  • Indicold Private Limited
  • Frialsa
  • Confederation Freezers (Premium Brands Holdings)
  • Vertical Cold Storage

 

Market Segmentation

 

Warehouse Type

  • Private
  • Public

 

Facility Type

  • Refrigerated Warehouse
  • Cold Rooms
  • Refrigerated Containers
  • Blast Freezers & Chillers
  • Other Facilities

 

Temperature Type

  • Chilled
  • Frozen
  • Deep Frozen

 

Structure Type

  • Civil Structure
  • Steel Structure
  • Hybrid Structure

 

Application

  • Dairy Products
  • Fish, Meat & Seafoods
  • Fruits & Vegetables
  • Bakery & Confectionery
  • Pharmaceuticals
  • Others

 

Geography

  • APAC
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Indonesia
  • North America
    • The US
    • Canada
  • Europe
    • The UK
    • Spain
    • Germany
    • France
    • Italy
    • Poland
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Chile
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • The UAE
    • Turkey

 

 

Check Out Some of the Latest Research Report that Can Boost your Business Decisions

Ice Storage Bins Market – Global Outlook & Forecast 2024-2029

https://www.arizton.com/market-reports/ice-storage-bins-market

Vaccine Storage and Packaging Market – Global Outlook & Forecast 2021-2026

https://www.arizton.com/market-reports/vaccine-storage-and-packaging-market

 

Why Arizton?                         

100% Customer Satisfaction                         

24×7 availability – we are always there when you need us                         

200+ Fortune 500 Companies trust Arizton’s report                         

80% of our reports are exclusive and first in the industry                         

100% more data and analysis                         

1500+ reports published till date                          

 

About Us:                                                              

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                            

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                             

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.            

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1-312-235-2040
Country: United States
Website: https://www.arizton.com/market-reports/cold-storage-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cold Storage Market to Hit USD 12.22 Billion by 2029 – Market Size, Share, Trend Analysis & Forecasts – Exclusive Research Report by Arizton

Soft Tissue Sarcoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Soft Tissue Sarcoma Pipeline Insight 2024” report provides comprehensive insights about 125+ companies and 130+ pipeline drugs in Soft Tissue Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Soft Tissue Sarcoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Soft Tissue Sarcoma Research. Learn more about our innovative pipeline today! @ Soft Tissue Sarcoma Pipeline Outlook

Key Takeaways from the Soft Tissue Sarcoma Pipeline Report

  • July 2024:- Epizyme Inc.- A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma. The participants of this study will have advanced epithelioid sarcoma. Sarcoma is a cancer of the connective tissues, such as nerves, muscles and bones. Epithelioid sarcoma is an ultra-rare sarcoma of the soft-tissue.
  • July 2024:- Nationwide Children’s Hospital- This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors. The proposed study will extend this evaluation to tumors that have been shown to either express known targets of cabozantinib or with preclinical evidence of efficacy, including specifically neuroblastomas.
  • DelveInsight’s Soft Tissue Sarcoma pipeline report depicts a robust space with 125+ active players working to develop 130+ pipeline therapies for Soft Tissue Sarcoma treatment.
  • The leading Soft Tissue Sarcoma Companies such as Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.
  • Promising Soft Tissue Sarcoma Therapies such as Retifanlimab, Gemcitabine, ADI PEG20, Ifosfamide, Chiauranib, INT230-6, Onfekafusp alfa, and others.

Stay informed about the cutting-edge advancements in Soft Tissue Sarcoma Treatments. Download for updates and be a part of the revolution in oncology care @ Soft Tissue Sarcoma Clinical Trials Assessment

Soft Tissue Sarcoma Emerging Drugs Profile

  • AL3818: Advenchen Laboratories

Anlotinib was developed by Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. as a new oral molecular RTK inhibitor; it targets VEGFR1, VEGFR3, VEGFR2/KDR, PDGFR-α, c-Kit, and FGFRs 1–3 and inhibits TA and tumor cell proliferation. Anlotinib may inhibit more targets than that do other RTK inhibitors, such as pazopanib, sunitinib, and sorafenib. The main mechanisms of action of anlotinib are as follows: preclinical studies have shown that anlotinib inhibits VEGF/PDGF-BB/FGF-2-induced cell migration, angiogenesis, and capillary-like tube formation in endothelial cells. More specifically, the mechanism involves the inhibition of the downstream ERK signaling pathway. Anlotinib has stronger anti-angiogenesis activity than that do other antiangiogenic agents (sunitinib and sorafenib). Currently, it is in Phase III stage of clinical trial evaluation to treat Soft Tissue Sarcoma.

  • L19 TNF: Philogen

Fibromun (L19TNF) is a fully-human immunomodulatory product consisting of the L19 antibody and TNF (a strong pro-inflammatory cytokine). (Recombinant TNF has so far been approved only for certain clinical applications). The fusion of TNF to the L19 antibody specific to the EDB domain of fibronectin results in a tumor-targeted product, which selectively localizes at the site of disease, while sparing healthy organs. Fibromun has shown potent anti-tumor activity, both as single agent and in combination with other drugs, in several immunocompetent preclinical models inducing in most cases long-lasting complete responses. Fibromun has previously been studied in clinical trials as monotherapy for systemic administration in patients with solid tumors and in melanoma patients using the Isolated Limb-Perfusion procedure. In preclinical models of sarcoma, Fibromun has, when combined with doxorubicin or dacarbazine (which are standard therapies for first line and third line sarcoma, respectively), cured all treated animals . Based on the encouraging results observed in the phase Ib study conducted in patients with metastatic Soft Tissue Sarcoma, three clinical trials with registration potential have started in Europe and in the United States. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Soft tissue sarcoma.

  • Camsirubicin: Monopar Therapeutics

Camsirubicin is a novel proprietary analog of the widely used cancer drug doxorubicin. Camsirubicin has been engineered specifically to retain the anticancer activity of doxorubicin while minimizing the toxic effects on the heart. Preclinical and early clinical studies support the hypothesis that camsirubicin will be less cardiotoxic while retaining anti-cancer activity. Monopar believes the results of these studies, along with the potential to combine a less or non-cardiotoxic analog of doxorubicin with other anticancer agents, emphasizes a large market opportunity for camsirubicin in a broad spectrum of cancer types. The antitumor effects of camsirubicin are mediated through mechanisms common to all anthracyclines including doxorubicin. These mechanisms include the stabilization of the topoisomerase II complex after a DNA strand break and DNA intercalation leading to apoptosis (cell death). Inhibiting the topoisomerase IIα isoform achieves the anticancer effect, while inhibiting the topoisomerase IIβ isoform, which is expressed in cardiomyocytes but not in cancer cells, mediates, at least in part, the cardiotoxicity associated with all anthracycline drugs currently used in the clinic. In contrast to doxorubicin, camsirubicin exhibits some selectivity for inhibiting the topoisomerase IIα isoform over the topoisomerase IIβ isoform. This selectivity may explain the minimal cardiotoxicity that camsirubicin has demonstrated in clinical studies to date.

Learn more about Soft Tissue Sarcoma Drugs opportunities in our groundbreaking Soft Tissue Sarcoma Research and development projects @ Soft Tissue Sarcoma Unmet Needs

Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.

Soft Tissue Sarcoma Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Discover the latest advancements in Soft Tissue Sarcoma Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Soft Tissue Sarcoma Market Drivers and Barriers, and Future Perspectives

Scope of the Soft Tissue Sarcoma Pipeline Report

  • Coverage- Global
  • Soft Tissue Sarcoma Companies- Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.
  • Soft Tissue Sarcoma Therapies- Retifanlimab, Gemcitabine, ADI PEG20, Ifosfamide, Chiauranib, INT230-6, Onfekafusp alfa, and others.
  • Soft Tissue Sarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Soft Tissue Sarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Soft Tissue Sarcoma Pipeline on our website @ Soft Tissue Sarcoma Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Soft Tissue Sarcoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Soft Tissue Sarcoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Anlotinib: Advenchen Laboratories, LLC
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Camsirubicin: Monopar Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. FHD-609: Foghorn Therapeutics
  15. Drug profiles in the detailed report…..
  16. Inactive Products
  17. Soft Tissue Sarcoma Key Companies
  18. Soft Tissue Sarcoma Key Products
  19. Soft Tissue Sarcoma- Unmet Needs
  20. Soft Tissue Sarcoma- Market Drivers and Barriers
  21. Soft Tissue Sarcoma- Future Perspectives and Conclusion
  22. Soft Tissue Sarcoma Analyst Views
  23. Soft Tissue Sarcoma Key Companies
  24. Appendix 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Soft Tissue Sarcoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Idiopathic Pulmonary Fibrosis Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Idiopathic Pulmonary Fibrosis Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the Idiopathic Pulmonary Fibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Idiopathic Pulmonary Fibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Idiopathic Pulmonary Fibrosis Research. Learn more about our innovative pipeline today! @ Idiopathic Pulmonary Fibrosis Pipeline Outlook

Key Takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report

  • June 2024:- Tvardi Therapeutics, Incorporated- REVERT-IPF: A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis. The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
  • June 2024:- Pliant Therapeutics, Inc.- A Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy and Safety of Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis (BEACON-IPF). The study will consist of an up to 35-day Screening Period, a 52-week Treatment Period, and a 14 day Safety Follow-up Period. Of note, participants who are not taking background therapy at study entry will be allowed to initiate it at any time during the study.
  • June 2024:- Bristol-Myers Squibb- A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis. The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
  • DelveInsight’s Idiopathic Pulmonary Fibrosis pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Idiopathic Pulmonary Fibrosis treatment.
  • The leading Idiopathic Pulmonary Fibrosis Companies such as FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma co, Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, Bridge Biotherapeutics, AstraZeneca, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd., Ark Biosciences, Ocean Biomedical, and others.
  • Promising Idiopathic Pulmonary Fibrosis Therapies such as Pirfenidone, Deupirfenidone, SC1011, TTI-101, PLN-74809, GSK3915393, and others.

Stay informed about the cutting-edge advancements in Idiopathic Pulmonary Fibrosis Treatments. Download for updates and be a part of the revolution in respiratory disease care @ Idiopathic Pulmonary Fibrosis Clinical Trials Assessment

Idiopathic Pulmonary Fibrosis Emerging Drugs

  • Pamrevlumab: FibroGen

Pamrevlumab is a proprietary therapeutic antibody developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. Pamrevlumab represents a potential treatment for a broad array of fibrotic and proliferative disorders that affect organ systems throughout the body. Currently, the drug is in the Phase III stage of its development for the treatment of Idiopathic Pulmonary Fibrosis.

  • Tipelukast: MediciNova

MN-001 (tipelukast) is a novel, orally bioavailable small molecule compound which exerts its effects through several mechanisms to produce its anti-fibrotic and anti-inflammatory activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). The 5-LO/LT pathway has been postulated as a pathogenic factor in fibrosis development and MN-001’s inhibitory effect on 5-LO and the 5-LO/LT pathway is considered to be a novel approach to treat fibrosis. MN-001 has been shown to down-regulate expression of genes that promote fibrosis including LOXL2, Collagen Type 1 and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation including CCR2 and MCP-1. In addition, histopathological data shows that MN-001 reduces fibrosis in multiple animal models. The US Food and Drug Administration (FDA) has granted orphan-drug designation to MN-001 (tipelukast) for treatment of idiopathic pulmonary fibrosis (IPF). Currently, the drug is in the Phase II stage of its development for the treatment of IPF.

  • PLN-74809: Pliant Therapeutics

PLN-74809 is an oral small-molecule dual-selective inhibitor of αvβ6 and αvβ1 integrins for the treatment of IPF. While present at very low levels in healthy tissues, these integrins are upregulated in the lungs of IPF patients where they activate TGF-β, a key driver of the fibrotic process. Blocking these integrins is designed to stop TGF-β activation, potentially halting the growth of scar tissue. PLN-74809 has received Fast Track Designation and Orphan Drug Designation from the US Food and Drug Administration (FDA) in IPF and Orphan Drug Designation from the European Medicines Agency (EMA) in IPF. The company has completed enrollment in the Phase 2a clinical trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF) and announced positive data from the trial.

  • HZN-825: Horizon Pharmaceuticals

HZN-825 is an oral selective LPAR1 antagonist that has shown early signs of clinical impact in systemic sclerosis. LPAR1 signaling has been implicated in fibrosis and inflammation, and preclinical and clinical evidence support the antifibrotic potential of LPAR1 antagonism across multiple organ systems, including both lung and skin. Currently, the drug is in the Phase II stage of its development for the treatment of Idiopathic Pulmonary Fibrosis.

  • Brilaroxazine: Reviva Pharmaceuticals

Brilaroxazine, a novel serotonin-dopamine modulator with multifaceted activities has the potential to treat idiopathic pulmonary fibrosis (IPF). Serotonin (5-HT) signaling plays a key role, via 5-HT2A/2B/7 receptors, in the vasoactive effect on pulmonary arteries and lung myofibroblast actions. Brilaroxazine displays a high affinity and functional activity for the 5-HT2A/2B/7 receptors and moderate affinity for the serotonin transporter. Brilaroxazine’s effects on vascular fibrosis (5-HT2B receptor), proliferation (5-H2A/2B receptor), relaxation (5-HT2A receptor), inflammation (5-HT7 receptor), and pro-inflammatory cytokines have created interest in the potential to treat IPF. Brilaroxazine was evaluated in a bleomycin (BLM)-induced rat model of IPF receiving either brilaroxazine 15 mg twice daily for 21 days starting at day 1 (BT) or at day 10 (BI) and demonstrated efficacy with significant improvements in key endpoints in the bleomycin (BLM)-induced rat model of IPF. Currently, the drug is in the Phase I stage of its development for the treatment of IPF.

Learn more about Idiopathic Pulmonary Fibrosis Drugs opportunities in our groundbreaking Idiopathic Pulmonary Fibrosis Research and development projects @ Idiopathic Pulmonary Fibrosis Unmet Needs

Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical

Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Discover the latest advancements in Idiopathic Pulmonary Fibrosis Treatment by visiting our website. Stay informed about how we’re transforming the future of respiratory disease @ Idiopathic Pulmonary Fibrosis Market Drivers and Barriers, and Future Perspectives

Scope of the Idiopathic Pulmonary Fibrosis Pipeline Report

  • Coverage- Global
  • Idiopathic Pulmonary Fibrosis Companies- FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma co, Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, Bridge Biotherapeutics, AstraZeneca, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd., Ark Biosciences, Ocean Biomedical, and others.
  • Idiopathic Pulmonary Fibrosis Therapies- Pirfenidone, Deupirfenidone, SC1011, TTI-101, PLN-74809, GSK3915393, and others.
  • Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Idiopathic Pulmonary Fibrosis Pipeline on our website @ Idiopathic Pulmonary Fibrosis Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Idiopathic Pulmonary Fibrosis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Idiopathic Pulmonary Fibrosis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Pamrevlumab: FibroGen
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Tipelukast: MediciNova
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Brilaroxazine: Reviva Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Idiopathic Pulmonary Fibrosis Key Companies
  21. Idiopathic Pulmonary Fibrosis Key Products
  22. Idiopathic Pulmonary Fibrosis- Unmet Needs
  23. Idiopathic Pulmonary Fibrosis- Market Drivers and Barriers
  24. Idiopathic Pulmonary Fibrosis- Future Perspectives and Conclusion
  25. Idiopathic Pulmonary Fibrosis Analyst Views
  26. Idiopathic Pulmonary Fibrosis Key Companies
  27. Appendix 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Idiopathic Pulmonary Fibrosis Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

WSIMLogiX Elevates Online Success for Businesses with Expert SEO Services

WSIMLogiX Elevates Online Success for Businesses with Expert SEO Services
Discover how WSIMLogiX boosts business success with expert SEO services, driving growth and ROI in the competitive digital landscape.

Danville, California – July 2, 2024 – WSIMLogiX, the leading digital marketing and advertising agency offers advanced, customizable digital marketing solutions designed to help businesses unlock their full revenue potential. Specializing in SEO services, WSIMLogiX is the best Bay Area SEO company, offering unparalleled expertise to drive online growth and customer retention for businesses of all sizes.

Untitled

Over the years, their top-tier SEO services companies not only reach their business goals but also maintain a competitive edge in the digital marketplace. Leveraging their team of seasoned Bay Area SEO experts, WSIMLogiX crafts strategic campaigns tailored to meet the unique needs of each client, facilitating quick, sustainable growth and impressive returns on investment (ROIs).

“Our team is unrivaled in its ability to create an outstanding online presence for any company, whether it’s a start-up or a well-established business,” says a spokesperson for the company. “We understand that every business is different, and that’s why we offer customizable solutions to ensure our clients stand out online and make a lasting impression on their customers.”

As one of the certified SEO services Bay Area, WSIMLogiX combines advanced strategies with industry-leading experience to elevate the customer journey from start to finish. They offer an array of services including SEO, Google Ads, web development, social media marketing, email marketing, and more.

The agency’s commitment to fast-paced results means clients can expect to see remarkable growth earlier than expected. By investing in WSIMLogiX’s services on SEO Bay Area, businesses can watch their revenue soar and realize impressive ROIs, positioning themselves for long-term success in the ever-evolving digital landscape.

“The market segments that we currently serve include Quick service restaurant chains, health care, and medical insurance, finance service, industrial automation, and more. Our focus is to get the right customers to the right businesses all the time that significantly increases brand awareness and profitable revenue,” said the spokesperson.

To know more about their marketing services or to schedule a consultation, visit the company’s website.

About Company:

WSIMLogiX is one of the recognized companies offering tailored digital marketing strategies that help businesses grow. To know more, visit https://wsimlogix.com/

Media Contact
Company Name: WSIMlogiX
Contact Person: Niveditha Jain
Email: Send Email
Phone: +1 (408) 341-5845
Address:3005 Drysdale St
City: Danville
State: California
Country: United States
Website: https://wsimlogix.com/

ANCA Vasculitis Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “ANCA Vasculitis Pipeline Insight 2024” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in ANCA Vasculitis pipeline landscape. It covers the ANCA Vasculitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ANCA Vasculitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in ANCA Vasculitis Research. Learn more about our innovative pipeline today! @ ANCA Vasculitis Pipeline Outlook

Key Takeaways from the ANCA Vasculitis Pipeline Report

  • June 2024:- Amgen- A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis. The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
  • June 2024:- Alpine Immune Sciences Inc.- An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3). The goal of this clinical study is to evaluate multiple dose levels of povetacicept (ALPN-303) in adults with immunoglobulin A (IgA) nephropathy, membranous nephropathy, lupus-related kidney disease (lupus nephritis). or anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis to determine if povetacicept is safe and potentially beneficial in treating these diseases.
  • DelveInsight’s ANCA Vasculitis pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for ANCA Vasculitis treatment.
  • The leading ANCA Vasculitis Companies such as Bristol-Myers Squibb, Travere Therapeutics, Novartis Pharmaceuticals, NS Pharma, Staidson Biopharmaceuticals Co., Ltd., and others.
  • Promising ANCA Vasculitis Therapies such as BDB-001 injection, Cyclophosphamide, Glucocorticoids, Avacopan, Iptacopan, NM8074, and others.

Stay informed about the cutting-edge advancements in ANCA Vasculitis Treatments. Download for updates and be a part of the revolution in Cardiovascular Diseases care @ ANCA Vasculitis Clinical Trials Assessment

ANCA Vasculitis Emerging Drugs Profile

  • Abatacept: Bristol-Myers Squibb

Abatacept is a selective T-cell co-stimulation modulator. Abatacept binds to CD80 and CD86 receptors on antigen-presenting cells (APCs), which are essential for T-cell activation. This binding blocks the interaction between CD80/CD86 and CD28, thereby inhibiting the delivery of the second co-stimulatory signal required for optimal T-cell activation. Currently, the drug is in Phase III stage of its clinical trial for the treatment of ANCA Vasculitis.

  • Sparsentan : Travere Therapeutics

Sparsentan is a dual endothelin and angiotensin II receptor antagonist used to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Sparsentan acts as a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R), which are involved in the pathogenesis of IgAN. It selectively blocks the action of endothelin-1 (ET-1) and angiotensin II (Ang II) at their respective receptors, thereby reducing proteinuria. The drug is currently in Phase II of clinical trial evaluation for the treatment of ANCA Associated Vasculitis.

Learn more about ANCA Vasculitis Drugs opportunities in our groundbreaking ANCA Vasculitis Research and development projects @ ANCA Vasculitis Unmet Needs

ANCA Vasculitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

ANCA Vasculitis Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Discover the latest advancements in ANCA Vasculitis Treatment by visiting our website. Stay informed about how we’re transforming the future of cardiovascular disease @ ANCA Vasculitis Market Drivers and Barriers, and Future Perspectives

Scope of the ANCA Vasculitis Pipeline Report

  • Coverage- Global
  • ANCA Vasculitis Companies- Bristol-Myers Squibb, Travere Therapeutics, Novartis Pharmaceuticals, NS Pharma, Staidson Biopharmaceuticals Co., Ltd., and others.
  • ANCA Vasculitis Therapies- BDB-001 injection, Cyclophosphamide, Glucocorticoids, Avacopan, Iptacopan, NM8074, and others.
  • ALK-positive Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • ALK-positive Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of ANCA Vasculitis Pipeline on our website @ ANCA Vasculitis Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. ANCA Vasculitis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. ANCA Vasculitis – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Abatacept: Bristol-Myers Squibb
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Sparsentan: Travere Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. Drug name: Company name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. ANCA Vasculitis Key Companies
  21. ANCA Vasculitis Key Products
  22. ANCA Vasculitis- Unmet Needs
  23. ANCA Vasculitis- Market Drivers and Barriers
  24. ANCA Vasculitis- Future Perspectives and Conclusion
  25. ANCA Vasculitis Analyst Views
  26. ANCA Vasculitis Key Companies
  27. Appendix 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ANCA Vasculitis Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight